| Year |
Citation |
Score |
| 2021 |
Lai D, Alipanahi B, Fontanillas P, Schwantes-An TH, Aasly J, Alcalay RN, Beecham GW, Berg D, Bressman S, Brice A, Brockman K, Clark L, Cookson M, Das S, Van Deerlin V, ... ... Langston JW, et al. Genome-wide association studies of LRRK2 modifiers of Parkinson's disease. Annals of Neurology. PMID 33938021 DOI: 10.1002/ana.26094 |
0.697 |
|
| 2020 |
Eis PS, Huang N, Langston JW, Hatchwell E, Schüle B. Loss-of-Function Mutation May Link Parkinson's Disease to Recessive Complex I Deficiency. Frontiers in Neurology. 11: 555961. PMID 33224084 DOI: 10.3389/fneur.2020.555961 |
0.681 |
|
| 2020 |
San Luciano M, Tanner CM, Meng C, Marras C, Goldman SM, Lang AE, Tolosa E, Schüle B, Langston JW, Brice A, Corvol JC, Goldwurm S, Klein C, Brockman S, Berg D, et al. Nonsteroidal Anti-Inflammatory Use and LRRK2 Parkinson's Disease Penetrance. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 32662532 DOI: 10.1002/mds.28189 |
0.679 |
|
| 2018 |
Foltynie T, Langston JW. Therapies to Slow, Stop, or Reverse Parkinson's Disease. Journal of Parkinson's Disease. 8: S115-S121. PMID 30584162 DOI: 10.3233/JPD-181481 |
0.358 |
|
| 2018 |
Zafar F, Valappil RA, Kim S, Johansen KK, Chang ALS, Tetrud JW, Eis PS, Hatchwell E, Langston JW, Dickson DW, Schüle B. Genetic fine-mapping of the Iowan gene triplication in a patient with Parkinson's disease. Npj Parkinson's Disease. 4: 18. PMID 29928688 DOI: 10.1038/S41531-018-0054-4 |
0.672 |
|
| 2018 |
Quansah E, Peelaerts W, Langston JW, Simon DK, Colca J, Brundin P. Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration. Molecular Neurodegeneration. 13: 28. PMID 29793507 DOI: 10.1186/s13024-018-0260-x |
0.33 |
|
| 2018 |
Langston JW, Wiley JC, Tagliati M. Optimizing Parkinson's disease diagnosis: the role of a dual nuclear imaging algorithm. Npj Parkinson's Disease. 4: 5. PMID 29507872 DOI: 10.1038/S41531-018-0041-9 |
0.374 |
|
| 2018 |
Lee K, Nguyen KD, Sun C, Liu M, Zafar F, Saetern J, Flierl A, Tetrud JW, Langston JW, Dickson D, Schüle B. LRRK2 p.Ile1371Val Mutation in a Case with Neuropathologically Confirmed Multi-System Atrophy. Journal of Parkinson's Disease. 8: 93-100. PMID 29480226 DOI: 10.3233/Jpd-171237 |
0.696 |
|
| 2017 |
Schüle B, McFarland KN, Lee K, Tsai YC, Nguyen KD, Sun C, Liu M, Byrne C, Gopi R, Huang N, Langston JW, Clark T, Gil FJJ, Ashizawa T. Parkinson's disease associated with pure ATXN10 repeat expansion. Npj Parkinson's Disease. 3: 27. PMID 28890930 DOI: 10.1038/S41531-017-0029-X |
0.633 |
|
| 2017 |
Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, Burn D, Halliday GM, Bezard E, Przedborski S, Lehericy S, Brooks DJ, Rothwell JC, Hallett M, DeLong MR, ... ... Langston JW, et al. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Movement Disorders : Official Journal of the Movement Disorder Society. 32: 1264-1310. PMID 28887905 DOI: 10.1002/Mds.27115 |
0.361 |
|
| 2016 |
Sherer TB, Frasier MA, Langston JW, Fiske BK. Parkinson's disease is ready for precision medicine. Personalized Medicine. 13: 405-407. PMID 29767601 DOI: 10.2217/pme-2016-0052 |
0.368 |
|
| 2016 |
Langston JW, Schüle B, Rees L, Nichols RJ, Barlow C. Erratum: Multisystem Lewy body disease and the other parkinsonian disorders. Nature Genetics. 48: 473. PMID 27023778 DOI: 10.1038/ng0329-473b |
0.624 |
|
| 2015 |
Schüle B, Byrne C, Rees L, Langston JW. Is PARKIN parkinsonism a cancer predisposition syndrome? Neurology. Genetics. 1: e31. PMID 27066568 DOI: 10.1212/NXG.0000000000000031 |
0.606 |
|
| 2015 |
Langston JW, Schüle B, Rees L, Nichols RJ, Barlow C. Multisystem Lewy body disease and the other parkinsonian disorders. Nature Genetics. 47: 1378-84. PMID 26620112 DOI: 10.1038/ng.3454 |
0.674 |
|
| 2015 |
Schüle B, Hatchwell E, Eis PS, Langston JW. Comparative genomic hybridization solves a 14-year-old PARKIN mystery. Annals of Neurology. 78: 663-4. PMID 26179350 DOI: 10.1002/ana.24478 |
0.568 |
|
| 2015 |
Koga S, Aoki N, Uitti RJ, van Gerpen JA, Cheshire WP, Josephs KA, Wszolek ZK, Langston JW, Dickson DW. When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology. 85: 404-12. PMID 26138942 DOI: 10.1212/Wnl.0000000000001807 |
0.304 |
|
| 2015 |
Kalia LV, Lang AE, Hazrati LN, Fujioka S, Wszolek ZK, Dickson DW, Ross OA, Van Deerlin VM, Trojanowski JQ, Hurtig HI, Alcalay RN, Marder KS, Clark LN, Gaig C, Tolosa E, ... ... Langston JW, et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. Jama Neurology. 72: 100-5. PMID 25401511 DOI: 10.1001/Jamaneurol.2014.2704 |
0.373 |
|
| 2014 |
Flierl A, Oliveira LM, Falomir-Lockhart LJ, Mak SK, Hesley J, Soldner F, Arndt-Jovin DJ, Jaenisch R, Langston JW, Jovin TM, Schüle B. Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplication. Plos One. 9: e112413. PMID 25390032 DOI: 10.1371/Journal.Pone.0112413 |
0.693 |
|
| 2014 |
Riley BE, Gardai SJ, Emig-Agius D, Bessarabova M, Ivliev AE, Schüle B, Alexander J, Wallace W, Halliday GM, Langston JW, Braxton S, Yednock T, Shaler T, Johnston JA. Systems-based analyses of brain regions functionally impacted in Parkinson's disease reveals underlying causal mechanisms. Plos One. 9: e102909. PMID 25170892 DOI: 10.1371/Journal.Pone.0102909 |
0.68 |
|
| 2014 |
Sanders LH, Laganière J, Cooper O, Mak SK, Vu BJ, Huang YA, Paschon DE, Vangipuram M, Sundararajan R, Urnov FD, Langston JW, Gregory PD, Zhang HS, Greenamyre JT, Isacson O, et al. LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction. Neurobiology of Disease. 62: 381-6. PMID 24148854 DOI: 10.1016/J.Nbd.2013.10.013 |
0.641 |
|
| 2013 |
Gardai SJ, Mao W, Schüle B, Babcock M, Schoebel S, Lorenzana C, Alexander J, Kim S, Glick H, Hilton K, Fitzgerald JK, Buttini M, Chiou SS, McConlogue L, Anderson JP, ... ... Langston JW, et al. Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease. Plos One. 8: e71634. PMID 24058406 DOI: 10.1371/Journal.Pone.0071634 |
0.395 |
|
| 2012 |
Brundin P, Langston JW. Journal of Parkinson's Disease--an excellent first year and a new sister. Journal of Parkinson's Disease. 2: 77. PMID 23933746 DOI: 10.3233/JPD-2012-12901 |
0.326 |
|
| 2012 |
Goldman SM, Kamel F, Ross GW, Bhudhikanok GS, Hoppin JA, Korell M, Marras C, Meng C, Umbach DM, Kasten M, Chade AR, Comyns K, Richards MB, Sandler DP, Blair A, ... Langston JW, et al. Genetic modification of the association of paraquat and Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 1652-8. PMID 23045187 DOI: 10.1002/mds.25216 |
0.308 |
|
| 2012 |
Wang C, Cai Y, Zheng Z, Tang BS, Xu Y, Wang T, Ma J, Chen SD, Langston JW, Tanner CM, Chan P. Penetrance of LRRK2 G2385R and R1628P is modified by common PD-associated genetic variants. Parkinsonism & Related Disorders. 18: 958-63. PMID 22658533 DOI: 10.1016/j.parkreldis.2012.05.003 |
0.325 |
|
| 2012 |
Mak SK, Huang YA, Iranmanesh S, Vangipuram M, Sundararajan R, Nguyen L, Langston JW, Schüle B. Small molecules greatly improve conversion of human-induced pluripotent stem cells to the neuronal lineage. Stem Cells International. 2012: 140427. PMID 22567022 DOI: 10.1155/2012/140427 |
0.606 |
|
| 2011 |
Mak SK, Tewari D, Tetrud JW, Langston JW, Schüle B. Mitochondrial dysfunction in skin fibroblasts from a Parkinson's disease patient with an alpha-synuclein triplication. Journal of Parkinson's Disease. 1: 175-83. PMID 23934919 DOI: 10.3233/JPD-2011-11025 |
0.653 |
|
| 2011 |
Brundin P, Langston JW. Journal of Parkinson's disease. Journal of Parkinson's Disease. 1: 1. PMID 23934894 DOI: 10.3233/Jpd-2011-10022 |
0.372 |
|
| 2011 |
Byers B, Cord B, Nguyen HN, Schüle B, Fenno L, Lee PC, Deisseroth K, Langston JW, Pera RR, Palmer TD. SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress. Plos One. 6: e26159. PMID 22110584 DOI: 10.1371/Journal.Pone.0026159 |
0.705 |
|
| 2011 |
Jenner P, Langston JW. Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 2316-23. PMID 21953831 DOI: 10.1002/Mds.23926 |
0.324 |
|
| 2011 |
Do CB, Tung JY, Dorfman E, Kiefer AK, Drabant EM, Francke U, Mountain JL, Goldman SM, Tanner CM, Langston JW, Wojcicki A, Eriksson N. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. Plos Genetics. 7: e1002141. PMID 21738487 DOI: 10.1371/Journal.Pgen.1002141 |
0.355 |
|
| 2011 |
Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez HH, ... ... Langston JW, et al. Rotenone, paraquat, and Parkinson's disease. Environmental Health Perspectives. 119: 866-72. PMID 21269927 DOI: 10.1289/Ehp.1002839 |
0.4 |
|
| 2009 |
Schüle B, Pera RA, Langston JW. Can cellular models revolutionize drug discovery in Parkinson's disease? Biochimica Et Biophysica Acta. 1792: 1043-51. PMID 19733239 DOI: 10.1016/j.bbadis.2009.08.014 |
0.655 |
|
| 2009 |
Grimbergen YA, Langston JW, Roos RA, Bloem BR. Postural instability in Parkinson's disease: the adrenergic hypothesis and the locus coeruleus. Expert Review of Neurotherapeutics. 9: 279-90. PMID 19210201 DOI: 10.1586/14737175.9.2.279 |
0.355 |
|
| 2009 |
Bronstein J, Carvey P, Chen H, Cory-Slechta D, DiMonte D, Duda J, English P, Goldman S, Grate S, Hansen J, Hoppin J, Jewell S, Kamel F, Koroshetz W, Langston JW, et al. Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007. Environmental Health Perspectives. 117: 117-21. PMID 19165397 DOI: 10.1289/Ehp.11702 |
0.319 |
|
| 2009 |
Christine CW, Langston JW, Turner RS, Starr PA. The neurophysiology and effect of deep brain stimulation in a patient with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism. Journal of Neurosurgery. 110: 234-8. PMID 19099380 DOI: 10.3171/2008.8.JNS08882 |
0.321 |
|
| 2007 |
Langston JW, Tanner CM, Schüle B. Parkin gene variations and parkinsonism: association does not imply causation. Annals of Neurology. 61: 4-6. PMID 17262853 DOI: 10.1002/ana.21069 |
0.646 |
|
| 2006 |
Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Annals of Neurology. 59: 591-6. PMID 16566021 DOI: 10.1002/ana.20834 |
0.311 |
|
| 2006 |
Lang AE, Langston JW, Stoessl AJ, Brodsky M, Brooks DJ, Dhawan V, Elias WJ, Lozano AM, Moro E, Nutt JG, Stacy M, Turner D, Wooten GF. GDNF in treatment of Parkinson's disease: response to editorial. The Lancet. Neurology. 5: 200-2. PMID 16488373 DOI: 10.1016/S1474-4422(06)70359-3 |
0.311 |
|
| 2006 |
Sherer TB, Fiske BK, Svendsen CN, Lang AE, Langston JW. Crossroads in GDNF therapy for Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 136-41. PMID 16470786 DOI: 10.1002/mds.20861 |
0.314 |
|
| 2005 |
Marras C, Goldman S, Smith A, Barney P, Aston D, Comyns K, Korell M, Langston JW, Ross GW, Tanner CM. Smell identification ability in twin pairs discordant for Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 20: 687-93. PMID 15719425 DOI: 10.1002/mds.20389 |
0.301 |
|
| 2004 |
Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, Hubble J. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Archives of Neurology. 61: 1563-8. PMID 15477510 DOI: 10.1001/ARCHNEUR.61.10.1563 |
0.325 |
|
| 2004 |
Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, Hulihan M, Maraganore D, Gwinn-Hardy K, Wszolek Z, Dickson D, Langston JW. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Annals of Neurology. 55: 174-9. PMID 14755720 DOI: 10.1002/Ana.10846 |
0.312 |
|
| 2003 |
Tan LC, Tanner CM, Chen R, Chan P, Farrer M, Hardy J, Langston JW. Marked variation in clinical presentation and age of onset in a family with a heterozygous parkin mutation. Movement Disorders : Official Journal of the Movement Disorder Society. 18: 758-63. PMID 12815654 DOI: 10.1002/Mds.10432 |
0.32 |
|
| 2003 |
Lincoln S, Wiley J, Lynch T, Langston JW, Chen R, Lang A, Rogaeva E, Sa DS, Munhoz RP, Harris J, Marder K, Klein C, Bisceglio G, Hussey J, West A, et al. Parkin-proven disease: common founders but divergent phenotypes. Neurology. 60: 1605-10. PMID 12771249 DOI: 10.1212/01.Wnl.0000064289.49410.A9 |
0.311 |
|
| 2003 |
Chen R, Langston JW, Chan P. Screening of ferritin light polypeptide 460-461InsA mutation in Parkinson's disease patients in North America. Neuroscience Letters. 335: 144-6. PMID 12459518 DOI: 10.1016/s0304-3940(02)01185-0 |
0.383 |
|
| 2002 |
Langston JW. Parkinson's disease: current and future challenges. Neurotoxicology. 23: 443-50. PMID 12428715 DOI: 10.1016/s0161-813x(02)00098-0 |
0.331 |
|
| 2002 |
Schlossmacher MG, Frosch MP, Gai WP, Medina M, Sharma N, Forno L, Ochiishi T, Shimura H, Sharon R, Hattori N, Langston JW, Mizuno Y, Hyman BT, Selkoe DJ, Kosik KS. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. The American Journal of Pathology. 160: 1655-67. PMID 12000718 DOI: 10.1016/S0002-9440(10)61113-3 |
0.313 |
|
| 2001 |
Farrer M, Chan P, Chen R, Tan L, Lincoln S, Hernandez D, Forno L, Gwinn-Hardy K, Petrucelli L, Hussey J, Singleton A, Tanner C, Hardy J, Langston JW. Lewy bodies and parkinsonism in families with parkin mutations. Annals of Neurology. 50: 293-300. PMID 11558785 DOI: 10.1002/Ana.1132 |
0.392 |
|
| 2000 |
Langston JW, Tanner CM. Selegiline and Parkinson's disease: It's déjà vu - Again Neurology. 55: 1770-1771. PMID 11134369 |
0.335 |
|
| 2000 |
Snow BJ, Vingerhoets FJ, Langston JW, Tetrud JW, Sossi V, Calne DB. Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. Journal of Neurology, Neurosurgery, and Psychiatry. 68: 313-6. PMID 10675212 DOI: 10.1136/jnnp.68.3.313 |
0.327 |
|
| 1999 |
Markopoulou K, Langston JW. Candidate genes and Parkinson's disease: where to next? Neurology. 53: 1382-3. PMID 10534238 |
0.377 |
|
| 1999 |
Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, Langston JW. Parkinson disease in twins: an etiologic study. Jama. 281: 341-6. PMID 9929087 DOI: 10.1001/jama.281.4.341 |
0.36 |
|
| 1998 |
Langston JW. Epidemiology versus genetics in Parkinson's disease: progress in resolving an age-old debate. Annals of Neurology. 44: S45-52. PMID 9749572 DOI: 10.1002/ana.410440707 |
0.398 |
|
| 1998 |
Chan P, Jiang X, Forno LS, Di Monte DA, Tanner CM, Langston JW. Absence of mutations in the coding region of the α-synuclein gene in pathologically proven Parkinson's disease Neurology. 50: 1136-1137. PMID 9566408 |
0.331 |
|
| 1998 |
Chan P, Tanner CM, Jiang X, Langston JW. Failure to find the α-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease Neurology. 50: 513-514. PMID 9484385 |
0.35 |
|
| 1997 |
Langston JW. The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology. 47: S153-60. PMID 8959984 DOI: 10.1212/wnl.47.6_suppl_3.153s |
0.392 |
|
| 1994 |
Bloem BR, Beckley DJ, van Dijk JG, Zwinderman AH, Remler MP, Langston JW, Roos RA. Medium latency stretch reflexes in young-onset Parkinson's disease and MPTP-induced parkinsonism. Journal of the Neurological Sciences. 123: 52-8. PMID 8064321 DOI: 10.1016/0022-510x(94)90203-8 |
0.308 |
|
| 1993 |
Forno LS, DeLanney LE, Irwin I, Langston JW. Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations. Advances in Neurology. 60: 600-8. PMID 8380528 |
0.328 |
|
| 1993 |
Forno LS, DeLanney LE, Irwin I, Di Monte D, Langston JW. Astrocytes and Parkinson's disease. Progress in Brain Research. 94: 429-36. PMID 1287728 DOI: 10.1016/s0079-6123(08)61770-7 |
0.366 |
|
| 1992 |
Langston JW. [Search for the cause of Parkinson's disease]. Archivos De Neurobiologia. 54: 264-71. PMID 1811457 |
0.366 |
|
| 1992 |
Tetrud JW, Langston JW. Tremor in MPTP-induced parkinsonism. Neurology. 42: 407-10. PMID 1736174 DOI: 10.1212/wnl.42.2.407 |
0.367 |
|
| 1992 |
Tetrud JW, Langston JW. Protective and preventive therapeutic strategies: monoamine oxidase inhibitors. Neurologic Clinics. 10: 541-52. PMID 1584188 |
0.318 |
|
| 1992 |
Zweig RM, Singh A, Cardillo JE, Langston JW. The familial occurrence of Parkinson's disease. Lack of evidence for maternal inheritance. Archives of Neurology. 49: 1205-7. PMID 1288529 DOI: 10.1001/archneur.1992.00530350127029 |
0.361 |
|
| 1991 |
Di Monte D, Tetrud JW, Langston JW. Blood lactate in Parkinson's disease. Annals of Neurology. 29: 342-3. PMID 2042953 DOI: 10.1002/ana.410290323 |
0.318 |
|
| 1991 |
Koller WC, Langston JW, Hubble JP, Irwin I, Zack M, Golbe L, Forno L, Ellenberg J, Kurland L, Ruttenber AJ. Does a long preclinical period occur in Parkinson's disease? Neurology. 41: 8-13. PMID 2041599 |
0.346 |
|
| 1991 |
Langston JW, Koller WC. The next frontier in Parkinson's disease: presymptomatic detection. Neurology. 41: 5-7. PMID 2041592 DOI: 10.1212/wnl.41.5_suppl_2.5 |
0.344 |
|
| 1991 |
Koller WC, Langston JW, Hubble JP, Irwin I, Zack M, Golbe L, Forno L, Ellenberg J, Kurland L, Ruttenber AJ. Does a long preclinical period occur in Parkinson's disease? Geriatrics. 8-15. PMID 1894149 |
0.346 |
|
| 1990 |
Tetrud JW, Langston JW. MPTP-induced parkinsonism as a model for Parkinson's disease. Acta Neurologica Scandinavica. Supplementum. 126: 35-40. PMID 2694734 DOI: 10.1111/j.1600-0404.1989.tb01780.x |
0.381 |
|
| 1990 |
Langston JW. Predicting Parkinson's disease. Neurology. 40: suppl 70-4; discussi. PMID 2215975 |
0.317 |
|
| 1990 |
Bloem BR, Irwin I, Buruma OJ, Haan J, Roos RA, Tetrud JW, Langston JW. The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease. Journal of the Neurological Sciences. 97: 273-93. PMID 2205710 DOI: 10.1016/0022-510x(90)90225-c |
0.376 |
|
| 1990 |
Langston JW. Selegiline as neuroprotective therapy in Parkinson's disease: concepts and controversies. Neurology. 40: suppl 61-6; discussi. PMID 2120617 |
0.309 |
|
| 1990 |
Golbe LI, Langston JW, Shoulson I. Selegiline and Parkinson's disease. Protective and symptomatic considerations. Drugs. 39: 646-51. PMID 2112994 DOI: 10.2165/00003495-199039050-00002 |
0.369 |
|
| 1989 |
Tetrud JW, Langston JW, Garbe PL, Ruttenber AJ. Mild parkinsonism in persons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neurology. 39: 1483-7. PMID 2812327 DOI: 10.1212/wnl.39.11.1483 |
0.313 |
|
| 1989 |
Langston JW. Mechanisms underlying neuronal degeneration in Parkinson's disease: an experimental and theoretical treatise. Movement Disorders : Official Journal of the Movement Disorder Society. S15-25. PMID 2542782 DOI: 10.1002/mds.870040504 |
0.314 |
|
| 1988 |
Tetrud JW, Langston JW. R-(-)-deprenyl as a possible protective agent in Parkinson's disease. Journal of Neural Transmission. Supplementum. 25: 69-79. PMID 3123606 |
0.345 |
|
| 1987 |
Langston JW. MPTP: insights into the etiology of Parkinson's disease. European Neurology. 2-10. PMID 3556187 DOI: 10.1159/000116349 |
0.405 |
|
| 1987 |
Langston JW, Irwin I, Ricaurte GA. Neurotoxins, parkinsonism and Parkinson's disease. Pharmacology & Therapeutics. 32: 19-49. PMID 3295897 DOI: 10.1016/0163-7258(87)90062-3 |
0.408 |
|
| 1987 |
Langston JW. Parkinson's disease: current view. American Family Physician. 35: 201-6. PMID 3103408 |
0.317 |
|
| 1986 |
Forno LS, Langston JW, DeLanney LE, Irwin I, Ricaurte GA. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Annals of Neurology. 20: 449-55. PMID 3024555 DOI: 10.1002/ana.410200403 |
0.332 |
|
| 1985 |
Stern Y, Langston JW. Intellectual changes in patients with MPTP-induced parkinsonism. Neurology. 35: 1506-9. PMID 3875807 DOI: 10.1212/Wnl.35.10.1506 |
0.312 |
|
| 1985 |
Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology. 35: 949-56. PMID 3874373 DOI: 10.1212/wnl.35.7.949 |
0.317 |
|
| 1984 |
Langston JW, Ballard P. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 11: 160-5. PMID 6608979 DOI: 10.1017/s0317167100046333 |
0.35 |
|
| 1984 |
Calne DB, Langston JW. Aetiology of Parkinson's disease. Lancet (London, England). 2: 1457-9. PMID 6140548 DOI: 10.1016/s0140-6736(83)90802-4 |
0.366 |
|
| 1978 |
Langston JW, Forno LS. The hypothalamus in Parkinson disease. Annals of Neurology. 3: 129-33. PMID 350130 DOI: 10.1002/ana.410030207 |
0.309 |
|
| Show low-probability matches. |